TrialCancer communications (London, England)2024

Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.

Yan Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.